Acute myeloid (myelogenous, myelocytic) leukemia (AML) is a rapidly progressing blood cancer with an extremely poor overall prognosis. Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets.

Acute myeloid leukemia starts in the bone marrow. This is the soft inner parts of bones. With acute types of leukemia such as AML, bone marrow cells don’t mature the way they’re supposed to. These immature cells, often called blast cells, keep building up. AML predominantly affects the elderly population and this subgroup of patients has an exceptionally high level of unmet needs.

For over forty years, there have been no major advances in the treatment for AML. The AML space is filled with excitement because the first targeted FLT3 kinase inhibitor therapies are expected to change the treatment landscape. With the unmet needs of AML patients remaining critically high, there are many R&D strategies and opportunities are being used by drug makers to remain competitive. The survival of patients with AML remains dismal, especially for those who do not respond to first-line chemotherapies. Therefore, there are considerably high unmet needs within the indication.

GlobalData estimates the 2014 sales for AML at approximately $342 million across the 7MM covered in this report. The Pharmaceuticals and Healthcare market will increase by almost three-fold over the forecast period, reaching $932 million in 2024 at a CAGR of 10.5%. Annualized AML therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in four patient segments (including, young patients, elderly patients, refractory/relapsed patients and FLT3 mutated patients), are forecasted up to 2024.